That is because LGND recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. What is a Hammer Chart Pattern? A …
For a hedged play on Ligand Pharmaceuticals (LGND), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $155 covered call for a net debit in the $149.08 area. That is also the break-even stock price for the covered call.
While the PR spin employed by LGND's management is ingenious and certainly has levitated the stock price, investors appear to be buying a bill of goods at current share price levels. Our conclusion is that LGND is significantly overvalued at $158/share as ...
Seeking Alpha · 1mon
That’s why I found 10 stocks to buy instead of bitcoin ... return of sub 17%, CAT stock is up almost 31% in the past six months. The good times are back for this construction giant. Ligand Pharmaceuticals Inc (NASDAQ:LGND) is a new generation of ...
InvestorPlace · 2mon
Mr. Charles S. Berkman J.D. is Vice President, General Counsel, Secretary of the Company. He joined the Company in November 2001 and previously served as Associate General Counsel and Chief Patent Counsel for the Company (and Secretary since March 2007 ...
Reuters · 1mon
For a hedged play on Ligand Pharmaceuticals (LGND), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $155 covered call for a net debit in the $147.56 area. That is also the break-even stock price for the covered call.
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately ...
Finance Yahoo · 8mon
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of ...
Reuters · 1mon
Ligand Pharmaceuticals Inc. LGND is scheduled to report third-quarter 2017 results ... Quote Ligand’s shares have outperformed the industry so far this year. The stock has rallied 44.1% compared with the industry’s 3.9% increase. View photos Last ...
Dr. Nancy Ryan Gray, Ph.D., is Director of the Company. Dr. Gray currently serves as President and Chief Executive Officer of Gordon Research Conferences, a not-for-profit organization that arranges conferences in the biological, chemical, and physical ...
Reuters · 1mon